Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784068 · ClinicalTrials.gov registry record · Phase 2
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
A Phase 2 study of Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
- 20
- Study locations
NCT01784068 is a Phase 2 study of Chronic Myelogenous Leukemia that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 215 participants, below the 275-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT01784068, a Phase 2 study of Chronic Myelogenous Leukemia, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment
Conditions Studied
Interventions
- DRUG Nilotinib followed by treatment-free
Study Locations (20)
Other
- Novartis Investigative Site - Buenos Aires
- Novartis Investigative Site - Graz
- Novartis Investigative Site - Rankweil
- Novartis Investigative Site - Salzburg
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Charleroi
Florida
- Florida Cancer Specialists - Fort Myers
- Lakes Research - Miami Lakes
- H Lee Moffitt Cancer Center and Research Institute - Tampa
Kansas
- Cancer Center of Kansas - Wichita
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering - New York
Oregon
- Oregon Health Sciences University - Portland
South Carolina
- Cancer Centers of the Carolinas - Greenville
Tennessee
- Tennessee Oncology PLLC - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2013-03-19 |
| Est. Completion | 2025-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01784068
The ClinicalTrials.gov registry entry for NCT01784068 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (22% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Nilotinib followed by treatment-free is the first listed.
NCT01784068 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT01784068 about?
NCT01784068 is a clinical study titled "Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients". The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment
What is the current status of trial NCT01784068?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2013-03-19. Estimated completion is 2025-01-23.
What conditions does trial NCT01784068 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT01784068?
The interventions under investigation include: Nilotinib followed by treatment-free (DRUG).
Who is sponsoring clinical trial NCT01784068?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01784068 being conducted?
This trial has 20 study locations across Florida, Kansas, Massachusetts, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
ACTIVE NOT RECRUITING · Phase 2
-
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
ACTIVE NOT RECRUITING · Phase 2
-
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.